Form D · Biotechnology
Dracen Pharmaceuticals, Inc.
San Diego, CA · CIK 0001728955
Offering snapshot reported Aug 10, 2023 · SEC filing
- Reported sold
- $2.29M Offering amount: $2.79M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $2.74K Reported outside-investor minimum
- First sale
- Jun 11, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2023 | Initial | $2,285,000 | No comparison | 6 | SEC filing |
| Nov 10, 2021 | Initial | $8,584,398 | No comparison | 8 | SEC filing |
| Jan 24, 2018 | Initial | $8,488,896 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-489348
Source: Form D, filed Aug 10, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis M. Bilski | Executive |
| Thomas M. Estok | Director, Executive |
| Robert Jackson | Director |
| Jonathan Leff | Director |
| Drew Pardoll, M.D., Ph.D. | Director |
| Asher Rubin | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9276 Scranton Road #200
San Diego, CA, 92121
San Diego, CA, 92121